Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib (QUALIFY IPF)

Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.

Study Overview

• Status: Completed
• Conditions: Idiopathic Pulmonary Fibrosis
• Intervention / Treatment: Drug: Nintedanib

• Study Type: Observational
• Enrollment (Actual): 180

Contacts and Locations

Study Locations

• Greece
  • Alexandroupoli, Greece, 68100
    • University General Hospital of Evros
  • Athens, Greece, 11527
    • Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med.
  • Athens, Greece, 124 62
    • University General Hospital ATTIKON
  • Heraklion, Greece, 71100
    • University Hospital of Heraklion, University Pulmonology Cl
  • Ioannina, Greece, 45 500
    • Univ. Gen. Hosp. of Ioannina
  • Kerkyra, Greece, 49100
    • General Hospital of Kerkyra
  • Larissa, Greece, 41110
    • General University Hospital of Larissa
  • Patras, Greece, 26504
    • Univ. Gen. Hosp. of Patras
  • Thessaloniki, Greece, 57010
    • General Hospital of Thessaloniki "G. Papanikolaou"
  • Thessaloniki, Greece, 57010
    • A Pulmonology Clinic "G.Papanikolaou" Hospital Thessaloniki

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Newly diagnosed IPF patients initiating treatment with nintedanib according to their physician's clinical decision will be enrolled in this study. In details, patients will be eligible to enroll in the study if the fulfil all the inclusion criteria.

Description

Inclusion Criteria:

• Patients ≥40 years of age.
• Patients that have signed Informed Consent Form.
• Treatment naive patients with an initial IPF diagnosis no more than 3 months prior to enrolment according to 2011 American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) guidelines who are initiating treatment with nintedanib (as monotherapy for IPF) the latest on the enrollement day or have initiated treatment with nintedanib (as monotherapy for IPF) within the past 7 days prior to enrolment.
• Patients for whom the decision to prescribe therapy with nintedanib according to the locally approved product's Summary of Product Characteristics (SmPC) has already been taken prior to their enrolment in the study and is clearly separated from the physician's decision to include the patient in the current study.
• Patients that are able to read, understand and complete the study specific questionnaires.

Exclusion Criteria:

• Treatment with nintedanib for more than 7 days prior to study enrolment.
• Patients receiving a combination therapy of nintedanib & pirfenidone for IPF.
• Patients that meet any of the contraindications to the administration of the study drug nintedanib according to the approved SmPC.
• Prior treatment with pirfenidone or other treatment for IPF.
• Participation in an interventional study.
• Patients currently receive treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) before the initiation of therapy with nintedanib.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Subjects with Idiopathic Pulmonary Fibrosis	Drug: Nintedanib; diagnosed IPF patients initiating treatment with nintedanib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change from baseline in Health Related Quality of Life (HRQoL) using SGRQ score	St. George's Respiratory Questionnaire (SGRQ)	upto 52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
measurement of mean change from baseline of dyspnoea burden with modified Medical Research Council scale (mMRC) score	modified Medical Research Council scale (mMRC)	upto 12 months
measurement of mean change form baseline to the follow up period of cough burden with Cough-Visual Analogue scale (cough-VAS)	Cough-Visual Analogue scale (cough-VAS)	upto 12 months
Percentage of adhered patients to nintedanib treatment with Simplified Medication Adherence Questionnaire (SMAQ)	adapted for the treatment of idiopathic pulmonary fibrosis (IPF)	upto 52 weeks
measurement of mean change of anxiety in IPF patients treated with nintedanib from baseline to follow up period via Generalized Anxiety Disorder Screener (GAD-7) Questionnaire	Generalized Anxiety Disorder Screener (GAD-7) Questionnaire	upto 52 weeks
Percentage of patients that use LTOT	Long Term Oxygen Treatment (LTOT)	upto 52 weeks

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2019
• Primary Completion (Actual): February 22, 2023
• Study Completion (Actual): February 22, 2023

Study Registration Dates

• First Submitted: October 16, 2018
• First Submitted That Met QC Criteria: October 16, 2018
• First Posted (Actual): October 18, 2018

Study Record Updates

• Last Update Posted (Actual): July 11, 2023
• Last Update Submitted That Met QC Criteria: July 10, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Interstitial; Fibrosis; Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Nintedanib
• Other Study ID Numbers: 1199-0355

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

The data shared are the raw clinical study data sets.

• IPD Sharing Time Frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
• IPD Sharing Access Criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No